|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn953695085 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
160520s2016 nyua ob 001 0 eng |
| 010 |
|
|
|a 2020678497
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d N$T
|d EBLCP
|d OCLCF
|d YDX
|d SNK
|d DKU
|d AUW
|d IGB
|d D6H
|d VTS
|d AGLDB
|d AU@
|d G3B
|d S8J
|d S9I
|d STF
|d M8D
|d OCLCO
|d OCL
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 957127332
|a 987429367
|
| 020 |
|
|
|a 9781634855488
|q (ebook)
|
| 020 |
|
|
|a 1634855485
|
| 020 |
|
|
|z 1634855086
|q (hbk.)
|
| 020 |
|
|
|z 9781634855082
|q (hbk.)
|
| 029 |
1 |
|
|a AU@
|b 000062399765
|
| 035 |
|
|
|a (OCoLC)953695085
|z (OCoLC)957127332
|z (OCoLC)987429367
|
| 050 |
0 |
0 |
|a RC858.C95
|
| 060 |
|
4 |
|a WI 820
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 616.3/72
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Cystic and idiopathic pulmonary fibrosis :
|b risk factors, management and long-term health outcomes /
|c Lorenzo Robertson, editor.
|
| 264 |
|
1 |
|b New York :
|b Nova Biomedical,
|c [2016]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Pulmonary and respiratory diseases and disorders
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CONTENTS ; PREFACE; Chapter 1 CLINICAL MANIFESTATIONS OF CYSTIC FIBROSIS AND THEIR MANAGEMENT ; Abstract; List of Abbreviations; Introduction; Epidemiology; Molecular Biology; CFTR Gene; CFTR Biosynthesis; Structure of CFTR; Overview of CFTR Function; Pathophysiology; Types of Mutations; Class I Mutations; Class II Mutations; Class III Mutations; Class IV Mutations; Class V Mutations
|
| 505 |
8 |
|
|a Class VI MutationsEffect of CFTR Dysfunction on Various Tissues; Sweat Glands; Lung and Small Airways; Paranasal Sinuses; Pancreas; Intestines; Liver and Gallbladder; Reproductive Tract; Bones; Other Organ Systems; Management; Clinical Features; Differential Diagnosis; Overview of Treatment; Treatment of Pulmonary Disease; Treatment of Gastrointestinal Disease; Treatment of Endocrine Abnormalities; Other Aspects of Treatment; Novel Treatment Strategies; Outcome Measures; Pulmonary Function Testing; Imaging-Based Measures; Sputum Biomarkers; Blood-Based Biomarkers; Potential Difference
|
| 505 |
8 |
|
|a Sweat Chloride TestPrognosis and Risk Factors; Conclusion; Conflict of Interests; References; Biographical Sketch; Chapter 2 LIVER DISEASE IN CYSTIC FIBROSIS: PREVALENCE, RISK FACTORS, AND OUTCOMES ; Abstract; Introduction; Objective; Methods; Screening for Liver Disease; Physical Examination; Liver Biochemistry Studies; Echographic Examination; Hepatobiliary Scintigraphy; Analysis of Clinical and CFTR Genotype Data; Statistic Analysis; Results; Discussion; Conclusion; References; Chapter 3 LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS ; Abstract; Introduction
|
| 505 |
8 |
|
|a Selection of Patients for Lung TransplantationCriteria for Referral; Contraindications; Pre-Transplant Evaluation; Listing for Transplantation; Preparation for Transplantation; Surgical Issues and Technical Considerations; Post-Transplant Management; Peri-Operative Management and Complications; Delayed Onset and Chronic Complications; Post-Transplant Surveillance; Outcomes; Conclusion; References; Chapter 4 NEW CYSTIC FIBROSIS THERAPY ; Abstract; Introduction; Evolution of CF Therapy; Nutritional Management; Clinical Trials of Ivacaftor in Patients with the Gly551Asp CFTR Mutation
|
| 505 |
8 |
|
|a Clinical Trials of Ivacaftor in Patients with CFTR Mutation Other Than G551DTargeted Therapies for Patients with Phe508del CFTR Mutation; Targeted Therapies for Patients with Class I Mutation; Gene Therapy; Conclusion; References; Biographical Sketch; Chapter 5 DISTINCT PATTERNS OF PULMONARY INJURY AND FIBROSIS INDUCED BY INTRATRACHEAL AND SUBCUTANEOUS BLEOMYCIN IN THE MOUSE: RELEVANCE FOR DISTINCT FORMS OF HUMAN LUNG FIBROSIS ; Abstract; List of Abbreviations; Introduction; Results
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cystic fibrosis.
|
| 650 |
|
0 |
|a Pulmonary fibrosis.
|
| 650 |
|
2 |
|a Cystic Fibrosis
|x therapy
|
| 650 |
|
2 |
|a Cystic Fibrosis
|
| 650 |
|
2 |
|a Pulmonary Fibrosis
|
| 650 |
|
6 |
|a Mucoviscidose.
|
| 650 |
|
6 |
|a Fibrose pulmonaire.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Pulmonary fibrosis.
|2 fast
|0 (OCoLC)fst01083828
|
| 650 |
|
7 |
|a Cystic fibrosis.
|2 fast
|0 (OCoLC)fst00886186
|
| 700 |
1 |
|
|a Robertson, Lorenzo,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Cystic and idiopathic pulmonary fibrosis.
|d New York : [2016]
|z 9781634855082
|w (DLC) 2016942393
|
| 830 |
|
0 |
|a Pulmonary and respiratory diseases and disorders series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1286285
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4616178
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1286285
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 13013178
|
| 994 |
|
|
|a 92
|b IZTAP
|
